Wendall Wierenga Cytokinetics Inc (CYTK) insider trading activity

Wendall Wierenga is Director of CYTOKINETICS INC. Currently has a direct ownership of 32,345 shares of CYTK, which is worth approximately $1.26 Million. The most recent transaction as insider was on Jul 15, 2025, when has been sold 164 shares (Common Stock) at a price of $38.01 per share, resulting in proceeds of $6,233. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 32.3K

30.17% 3M change

32.34% 12M change

Total Value Held $1.26 Million

WENDALL WIERENGA Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 15 2025	BUY Grant, award, or other acquisition	$6,233 $38.01 p/Share	164 Added 0.5%	32,345 Common Stock
May 14 2025	BUY Grant, award, or other acquisition	-	7,333 Added 18.56%	32,181 Common Stock
Apr 21 2025	SELL Open market or private sale	$769,200 $38.46 p/Share	20,000 Reduced 44.6%	24,848 Common Stock
Apr 21 2025	BUY Exercise of conversion of derivative security	$124,200 $6.21 p/Share	20,000 Added 30.84%	44,848 Common Stock
Apr 15 2025	BUY Grant, award, or other acquisition	$6,246 $38.56 p/Share	162 Added 0.65%	24,848 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	$6,214 $48.93 p/Share	127 Added 0.51%	24,686 Common Stock
Dec 16 2024	SELL Open market or private sale	$36,068 $48.61 p/Share	742 Reduced 2.93%	24,559 Common Stock
Dec 16 2024	BUY Exercise of conversion of derivative security	$5,468 $7.37 p/Share	742 Added 2.85%	25,301 Common Stock
Nov 25 2024	SELL Open market or private sale	$37,100 $50.0 p/Share	742 Reduced 2.93%	24,559 Common Stock
Nov 25 2024	BUY Exercise of conversion of derivative security	$5,468 $7.37 p/Share	742 Added 2.85%	25,301 Common Stock
Oct 28 2024	SELL Open market or private sale	$232,617 $52.25 p/Share	4,452 Reduced 15.35%	24,559 Common Stock
Oct 28 2024	BUY Exercise of conversion of derivative security	$32,811 $7.37 p/Share	4,452 Added 13.3%	29,011 Common Stock
Oct 01 2024	BUY Grant, award, or other acquisition	$6,206 $52.6 p/Share	118 Added 0.48%	24,559 Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	114 Added 0.46%	24,441 Common Stock
May 15 2024	BUY Grant, award, or other acquisition	-	5,600 Added 18.71%	24,327 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	$6,224 $84.12 p/Share	74 Added 0.39%	18,727 Common Stock
Dec 27 2023	SELL Open market or private sale	$736,000 $73.6 p/Share	10,000 Reduced 34.9%	18,653 Common Stock
Dec 27 2023	BUY Exercise of conversion of derivative security	$44,400 $4.44 p/Share	10,000 Added 29.72%	23,653 Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	$12,490 $27.88 p/Share	448 Added 2.35%	18,653 Common Stock
Aug 21 2023	SELL Open market or private sale	$192,760 $32.02 p/Share	6,020 Reduced 24.85%	18,205 Common Stock
Aug 21 2023	BUY Exercise of conversion of derivative security	$40,454 $6.72 p/Share	6,020 Added 19.9%	24,225 Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	$12,476 $33.36 p/Share	374 Added 2.01%	18,205 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	5,000 Added 21.9%	17,831 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	$11,237 $37.71 p/Share	298 Added 2.27%	12,831 Common Stock
Feb 06 2023	SELL Open market or private sale	$315,000 $45.0 p/Share	7,000 Reduced 35.84%	12,533 Common Stock

Also insider at

CRNX

Crinetics Pharmaceuticals, Inc. Healthcare